Trials / Active Not Recruiting
Active Not RecruitingNCT05289661
Descemet Endothelial Thickness Comparison Trial I
Descemet Endothelial Thickness Comparison Trials (DETECT I & II)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on endothelial cell loss.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topical Ripasudil | To determine the effect of rho-kinase inhibitors on endothelial cell loss |
| DRUG | Topical Placebo | topical Placebo |
Timeline
- Start date
- 2022-07-15
- Primary completion
- 2026-11-30
- Completion
- 2027-11-30
- First posted
- 2022-03-21
- Last updated
- 2025-12-17
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05289661. Inclusion in this directory is not an endorsement.